ClinVar Miner

Submissions for variant NM_000059.4(BRCA2):c.8168A>C (p.Asp2723Ala)

dbSNP: rs41293513
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel, ClinGen RCV000113879 SCV004101442 pathogenic Breast-ovarian cancer, familial, susceptibility to, 2 2024-04-23 reviewed by expert panel curation The c.8168A>C variant in BRCA2 is a missense variant predicted to cause substitution of Aspartic acid by Alanine at amino acid 2723 (p.Asp2723Ala). This variant is present in gnomAD v2.1 (exomes only, non-cancer subset) or gnomAD v3.1 (non-cancer subset) but is below the ENIGMA BRCA1/2 VCEP threshold >0.00002 for BS1_Supporting (PM2_Supporting, BS1, and BA1 are not met). This BRCA2 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.576, above the recommended threshold of 0.30 for prediction of impact on BRCA2 function via protein change. SpliceAI predictor score of 0.00 suggests that the variant has no impact on splicing (score threshold <0.10) (PP3 met). Reported by two calibrated studies to exhibit protein function similar to pathogenic control variants (PMIDs: 33609447, 33293522) (PS3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 0.557 (based on Pathology LR=0.214; Co-occurrence LR=1.102; Family History LR=2.36), which is above the ENIGMA BRCA1/2 VCEP threshold for BP5 (>0.48) and below PP4 (<2.08) (BP5 and PP4 not met; 31853058, Internal lab contributors). Cosegregation analysis of family(ies) carrying this variant provided evidence towards pathogenicity, and has a Bayes Score of 74321.3, above the thresholds for Very strong pathogenic evidence (LR >350) (PP1_Very strong; Internal lab contributors). In summary, this variant meets the criteria to be classified as a Pathogenic variant variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PP3, PS3, PP1_Very strong).
Invitae RCV000045437 SCV000073450 likely pathogenic Hereditary breast ovarian cancer syndrome 2024-01-12 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with alanine, which is neutral and non-polar, at codon 2723 of the BRCA2 protein (p.Asp2723Ala). This variant is present in population databases (rs41293513, gnomAD 0.0009%). This missense change has been observed in individual(s) with breast cancer and/or ovarian cancer (PMID: 12601471, 28888541). ClinVar contains an entry for this variant (Variation ID: 52516). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (PMID: 33609447) indicates that this missense variant is expected to disrupt BRCA2 function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects BRCA2 function (PMID: 18451181, 24323938, 29394989, 29884841). This variant disrupts the p.Asp2723 amino acid residue in BRCA2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 15290653, 15695382, 16489001, 17924331, 18607349, 21990134). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
GeneDx RCV000200976 SCV000210465 likely pathogenic not provided 2019-06-20 criteria provided, single submitter clinical testing Not observed at a significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 12601471, 19043619, 21702907, 18724707, 18451181, 23108138, 26681312, 23893897, 25447315, 26269718, 17972171, 29394989, 31447099, 29884841)
Ambry Genetics RCV000218818 SCV000275234 pathogenic Hereditary cancer-predisposing syndrome 2020-02-12 criteria provided, single submitter clinical testing The p.D2723A pathogenic mutation (also known as c.8168A>C), located in coding exon 17 of the BRCA2 gene, results from an A to C substitution at nucleotide position 8168. The aspartic acid at codon 2723 is replaced by alanine, an amino acid with dissimilar properties. This alteration is non-functional in multiple protein functional assays including homology-directed DNA repair (HDR) assay (Guidugli L et al, Cancer Res. 2013 Jan; 73(1):265-75; Farrugia DJ et al., Cancer Res. 2008 May; 68(9):3523-31; Guidugli L et al. Am. J. Hum. Genet., 2018 Jan.). This variant occurs in a structural hotspot region of the protein and is predicted to destabilize the protein and disrupt the native protein-protein (BRCA2-DSS1) interaction (Ambry internal data; Yang et al. Science. 2002; 297(5588):1837-48). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this alteration is interpreted as a disease-causing mutation.
Counsyl RCV000113879 SCV000786073 likely pathogenic Breast-ovarian cancer, familial, susceptibility to, 2 2018-02-22 criteria provided, single submitter clinical testing
Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine RCV000113879 SCV000839923 likely pathogenic Breast-ovarian cancer, familial, susceptibility to, 2 2018-01-30 criteria provided, single submitter clinical testing A heterozygous c.8168A>C (p.D2723A) likely pathogenic variant in the BRCA2 gene was detected in this individual. This variant has been previously described in breast cancer (PMID: 12601471). Different missense changes at this codon, p.D2723H and p.D2723G, have been reported as pathogenic. In addition, experimental studies have shown that this variant results in reduced homology directed repair and increased centrosome amplification (PMID: 23108138, 18451181). Therefore, we consider this variant to be likely pathogenic.
Cancer Variant Interpretation Group UK, Institute of Cancer Research, London RCV000045437 SCV001478296 pathogenic Hereditary breast ovarian cancer syndrome 2018-09-25 criteria provided, single submitter curation Data used in classification: The variant was observed in 3 independent UK families undergoing clinical diagnostic BRCA1/BRCA2 testing for HBOC according to diagnostic criteria, the denominator of which dataset of clinical testing was 16,600. Case control comparison against ethnically matched population data (3/16,600 in familial cases against 1/55,659 gnomAD NFE controls) 2-sided Fishers exact: pexact= 0.037 (PS4_strong). The frequency of this variant is 0/67,264 individuals (remainder of the GNOMAD population) (PM2_mod). This variant is predicted deleterious on AlignGVGD (class: C65), SIFT (Deleterious), Polyphen2 HumVar (probably damaging) and CADD (18.82 (PP3_sup). This variant is at same codon as an established pathogenic variant on ClinVar (c.8168A>G). (PM5_mod). The variant is in the DNA-binding domain of BRCA2 (PM1_sup). In the BRCA2 Homology-Directed Repair Activity assay DNA Binding Domain assay (Guidugli et al Cancer Res 2013;73:265-275,Couch Lab), the variant has a probability of pathogenicity of P=1.0. In the VarCall Bayesian statistical model for VUS classification using functional assay data (Guidugli et al Am J Hum Genet 2018; 102:233-248, Couch Lab), the variant has a probability of being deleterious of 0.994 and an overall classification of pathogenic. (PS3_strong). This variant is classified on ClinVar as likely pathogenic by multiple accredited USA diagnostic laboratories (Ambry Genetics 2015, Counsyl 2018 and GeneDx 2017) (PP5_sup). Data not used in classification: There are additional reports of this variant in DMuDB (11), BIC (2), and BRCA2 LOVD (4).
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000045437 SCV004847867 likely pathogenic Hereditary breast ovarian cancer syndrome 2019-10-14 criteria provided, single submitter clinical testing The p.Asp2723Ala variant in BRCA2 has been reported in at least 4 individuals with breast caner (Scott 2003, Gorringe 2008, BIC database). It has also been identified in 1/113396 European chromosomes by gnomAD (http://gnomad.broadinstitute.org); however, this frequency is low enough to be consistent with the frequency of hereditary breast and ovarian cancer (HBOC) in the general population. This variant has also been reported in Clinvar (Variation ID: 52516). Computational prediction tools and conservation analyseis suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In vitro assays provide some evidence that this variant impact protein function (Guidugli 2018); however, these types of assays may not accurately represent biological function. Another variant involving this codon (p.Asp2723His) has been identified in individuals with breast cancer and has been classified as Pathogenic by the ClinGen-approved ENIGMA expert panel. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant hereditary breast and ovarian cancer syndrome (HBOC). ACMG/AMP Criteria applied: PM2, PS3_Moderate, PM5, PP3, PS4_Supporting.
Breast Cancer Information Core (BIC) (BRCA2) RCV000113879 SCV000147288 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 2 2003-12-23 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.